Indegene IPO listed @ Rs. 655

May 13, 2024 admin Leave a replyPost Comment

INDEGENE IPO GMP, Details to watch, Guidance & Subscription status @ Chanakyanipothi.com India`s Oldest & the most Trusted Investment website. Operational since 8th December 1999, this is the Only Investment website in India, which has successfully completed 23 Years.

INDEGENE IPO Promoters
The company is a professionally managed company and does not have an identifiable promoter.

INDEGENE IPO Company Details to watch

Indegene is a “digital-first” commercialization company focused exclusively on the global life sciences industry. Its solutions enable biopharmaceutical, emerging biotech and medical devices companies develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner. It achieves this by combining over two decades of healthcare domain expertise and fit-for-purpose technology. Its portfolio of solutions cover all aspects of commercial, medical, regulatory and R&D operations of life sciences companies.
It has established client relationships with each of the 20 largest biopharmaceutical companies in the world by revenue for the Financial Year 2023, having earned more than 69.00% of its total revenue from operations for each of the nine months ended December 31, 2023 and 2022 and the Financial Years 2023, 2022 and 2021 from these 20 customers.
As of December 31, 2023, it had 65 active clients. It delivers solutions to them from its operation hubs located across North America, Europe and Asia. It has internally developed artificial intelligence (“AI”) and machine learning (“ML”) based proprietary platforms, which allow it to offer its solutions across the globe at scale. Its delivery model allows it to operate where its clients are located. As of December 31, 2023, it had 5,181 full-time employees across 10countries, of which 4,510 employees were delivery employees (i.e., employees who do not belong to corporate and support functions). As of December 31, 2023, 20.49% of its delivery employees had healthcare-related educational backgrounds.

Given the breadth of its solutions, it believes that it is well positioned to benefit from the expected growth in life sciences operations expenditure, which was estimated at ?12.0 trillion (US$156 billion) in 2022 and is expected to grow at a CAGR of 6.5% to reach ?15.5 trillion (US$201 billion) in 2026. Sales and marketing was the largest segment of life sciences operations expenditure, contributing Rs.4.2 trillion (US$55 billion) or 35% of overall life sciences operations expenditure, but with a low outsourcing penetration rate of 7 –12%. However, outsourcing expenditure in this segment is projected to grow at a CAGR of approximately 14.5% between 2022 and 2026, representing room for growth
As of June 30, 2022, it had 52 active clients. It delivers solutions to them from its operation hubs located across North America, Europe and Asia. it has internally developed artificial intelligence (“AI”) and machine learning (“ML”) based proprietary platforms, which allows it to offer its solutions across the globe at scale. Its delivery model allows it to operate where its clients are located. As of June 30, 2022, it had 5,245 full-time employees across nine countries, of which 4,712 employees were delivery employees (i.e., employees who do not belong to corporate and support functions). As of June 30, 2022, 21.88% of its delivery employees had healthcare-related educational backgrounds.

For more information about the company, click www.indegene.com

Objects of the IPO
This is fresh issue of capital & offer for sale.
The Company proposes to utilise the Net Proceeds towards funding of the following objects:
1. Repayment/prepayment of indebtedness of one of its Subsidiaries, ILSL Holdings, Inc.;
2. Funding the capital expenditure requirements of its Company and our Material Subsidiary, Indegene, Inc.;
3. Payment of consideration towards acquisition of additional shares in DT Associates Limited by ILSL
Holdings, Inc., a Subsidiary; and
4. General corporate purposes and inorganic growth

INDEGENE IPO GMP Details to watch Guidance & Subscription

INDEGENE IPO GMP Details to watch Guidance & Subscription
Indegene is a “digital-first” commercialization company focused exclusively on the global life sciences industry. Its solutions enable biopharmaceutical, emerging biotech and medical devices companies develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner. Its portfolio of solutions cover all aspects of commercial, medical, regulatory and R&D operations of life sciences companies.
As of December 31, 2023, it had 65 active clients. It delivers solutions to them from its operation hubs located across North America, Europe and Asia. It has internally developed artificial intelligence (“AI”) and machine learning (“ML”) based proprietary platforms, which allow it to offer its solutions across the globe at scale. Its delivery model allows it to operate where its clients are located. As of December 31, 2023, it had 5,181 full-time employees across 10countries, of which 4,510 employees were delivery employees (i.e., employees who do not belong to corporate and support functions). As of December 31, 2023, 20.49% of its delivery employees had healthcare-related educational backgrounds.
It has established client relationships with each of the 20 largest biopharmaceutical companies in the world by revenue for the Financial Year 2023, having earned more than 69.00% of its total revenue from operations for each of the nine months ended December 31, 2023 and 2022.
Given the breadth of its solutions, it believes that it is well positioned to benefit from the expected growth in life sciences operations expenditure, which was estimated at Rs.12.0 trillion (US$156 billion) in 2022 and is expected to grow at a CAGR of 6.5% to reach Rs.15.5 trillion (US$201 billion) in 2026. Sales and marketing was the largest segment of life sciences operations expenditure, contributing Rs.4.2 trillion (US$55 billion) or 35% of overall life sciences operations expenditure, but with a low outsourcing penetration rate of 7 –12%. However, outsourcing expenditure in this segment is projected to grow at a CAGR of approximately 14.5% between 2022 and 2026, representing room for growth
Size of the IPO: The size of the IPO Rs. 1841.76 Crore is not very large looking to the investors’ appetite. Retail portion is just RS. 644.62 Crore and HNI portion is only Rs. 276.26 Crore. So huge oversubscription in all the 3 categories is expected.
Guidance: There are no listed peers. The company has huge growth potential and shares are offered at very attractive valuations. Do Apply and if you donot get allotment, do buy immediately on listing.

>>Go to Mainboard IPOs Section: Click
>>Go to SME IPOs Section: Click
>>Get Good Staff or Job, Click: Staffavailable.com
>>Interested in Used Automobiles or vintage cars? Click: BigGaddi.com
>>Get solid Guidance on Mutual fund Investments, Click: ChanakyaMFGuidance.com
>>Study Stock Research Reports, Click: AnalysisLibrary.com
>>Interested in Crossword Puzzles? Click: Magajmari.com

INDEGENE IPO GMP Guidance